Effects of Optimal Medical Treatment With or Without Coronary Revascularization on Angina and Subsequent Revascularizations in Patients With Type 2 Diabetes Mellitus and Stable Ischemic Heart Disease

Background-In the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, an initial strategy of coronary revascularization and optimal medical treatment (REV) compared with an initial optimal medical treatment with the option of subsequent revascularization (MED) did not reduce all-cause mortality or the composite of cardiovascular death, myocardial infarction, and stroke in patients with type 2 diabetes mellitus and stable ischemic heart disease. In the same population, we tested whether the REV strategy was superior to the MED strategy in preventing worsening and new angina and subsequent coronary revascularizations. Methods and Results-Among the 2364 men and women (mean age, 62.4 years) with type 2 diabetes mellitus, documented coronary artery disease, and myocardial ischemia, 1191 were randomized to the MED and 1173 to the REV strategy preselected in the percutaneous coronary intervention (796) and coronary artery bypass graft (377) strata. Compared with the MED strategy, the REV strategy at the 3-year follow-up had a lower rate of worsening angina (8% versus 13%; P < 0.001), new angina (37% versus 51%; P = 0.001), and subsequent coronary revascularizations (18% versus 33%; P < 0.001) and a higher rate of angina-free status (66% versus 58%; P = 0.003). The coronary artery bypass graft stratum patients were at higher risk than those in the percutaneous coronary intervention stratum, and had the greatest benefits from REV. Conclusions-In these patients, the REV strategy reduced the occurrence of worsening angina, new angina, and subsequent coronary revascularizations more than the MED strategy. The symptomatic benefits were observed particularly for high-risk patients.

National Heart, Lung, and Blood Institute (NHLBI/NIH)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[U01 HL061744]

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[U01 HL061746]

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[U01 HL061748]

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH)[U01 HL063804]

GlaxoSmithKline, Collegeville, PA

Lantheus Medical Imaging Inc., North Billerica, MA

Astellas Pharma US Inc., Deerfield, IL

Merck & Co Inc., Whitehouse Station, NJ

Abbott Laboratories Inc., Abbott Park, IL

Pfizer Inc., New York, NY

GlaxoSmithKline

Abbott

Sanofi-aventis

Boston Scientific

Medtronic